Application of proteomic technology in identifying pancreatic secretory trypsin inhibitor variants in urine of patients with pancreatitis

Clinical Chemistry

Volumn 52, Issue 1, 2006, Pages 73-81

  Valmu, Leena ^a   Paju, Annukka ^a   Lempinen, Marko ^b   Kemppainen, Esko ^b   Stenman, Ulf Håkan ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; ASPARAGINE; GENE PRODUCT; SERINE;

ADULT; ANTIBODY AFFINITY; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; MALE; MASS SPECTROMETRY; PANCREATITIS; PATHOGENESIS; POROSITY; PROTEIN DEGRADATION; PROTEIN PURIFICATION; PSTI VARIANT GENE; QUANTITATIVE DIAGNOSIS; SENSITIVITY AND SPECIFICITY; URINALYSIS;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; CARRIER PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PANCREATITIS, CHRONIC; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 29744456182     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.056861     Document Type: Article

References (31)

1. Haverback BJ, Dyce B, Bundy H, Edmonson HA. Trypsin, trypsinogen, and trypsin inhibitor in human pancreatic juice. Am J Med 1960;29:424-33.
2. Pubols MH, Bartelt DC, Greene LJ. Trypsin inhibitor from human pancreas and pancreatic juice. J Biol Chem 1974;249:2235-42.
3. Rinderknecht H. Activation of pancreatic zymogens. Normal activation, premature intrapancreatic activation, protective mechanisms against inappropriate activation. Dig Dis Sci 1986;31:314-21.
4. Stenman UH. Tumor-associated trypsin inhibitor. Clin Chem 2002;48:1206-9.
5. Huhtala ML, Pesonen K, Kalkkinen N, Stenman UH. Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 1982;257:13713-6.
6. Horii A, Kobayashi T, Tomita N, Yamamoto T, Fukushige, S, Murotsu T, et al. Primary structure of human pancreatic secretory trypsin inhibitor (PSTI) gene. Biochem Biophys Res Commun 1987;149:635-41.
7. Bartelt DC, Shapanka R, Greene U. The primary structure of the human pancreatic secretory trypsin inhibitor. Amino acid sequence of the reduced S-aminoethylated protein. Arch Biochem Biophys 1977;179:189-99.
8. Witt H, Luck W, Hennies HC, Classen M, Kage A, Lass U, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000;25:213-6.
9. Gomez-Lira M, Bonamini D, Castellani C, Unis L, Cavallini G, Assael B, et al. Mutations in the SPINK1 gene in idiopathic pancreatitis Italian patients. Eur J Hum Genet 2003;11:543-6.
10. Threadgold J, Greenhalf W, Ellis I, Howes N, Lerch MM, Simon P, et al: The N34S mutation of SPINK1 (PSTI) is associated with a familial pattern of idiopathic chronic pancreatitis but does not cause the disease. Gut 2002;50:675-81.
11. Lempinen M, Paju A, Kemppainen E, Smura T, Kylanpaa ML, Nevanlinna H, et al. Mutations N34S and P55S of the SPINK1 gene in patients with chronic pancreatitis or pancreatic cancer and in healthy subjects: a report from Finland. Scand J Gastroenterol 2005;40:225-30.
12. Schneider A. Serine protease inhibitor kazal type 1 mutations and pancreatitis. Clin Lab Med 2005;25:61-78.
13. Le Marechal C, Chen JM, Le Gall C, Plessis G, Chipponi J, Chuzhanova NA, et al. Two novel severe mutations in the pancreatic secretory trypsin inhibitor gene (SPINK1) cause familial and/or hereditary pancreatitis. Hum Mutat 2004;23:205.
14. Kuwata K, Hirota M, Shimizu H, Nakae M, Nishihara S, Takimoto A, et al. Functional analysis of recombinant pancreatic secretory trypsin inhibitor protein with amino-acid substitution. J Gastroenterol 2002;37:928-34.
15. Hirota M, Kuwata K, Ohmuraya M, Ogawa M. From acute to chronic pancreatitis: the role of mutations in the pancreatic secretory trypsin inhibitor gene. JOP 2003;4:83-8.
16. Tukiainen E, Kylanpaa ML, Kemppainen E, Nevanlinna H, Paju A, Repo H, et al. Pancreatic secretory trypsin inhibitor (SPINK1) gene mutations in patients with acute pancreatitis. Pancreas 2005;30:239-42.
17. 1-antitrypsin variants in plasma with the use of proteomic technology. Clin Chem 2001;47:2012-22.
18. Bergen HR 3rd, Zeldenrust SR, Butz ML, Snow DS, Dyck PJ, Klein CJ, et al. Identification of transthyretin variants by sequential proteomic and genomic analysis. Clin Chem 2004;50:1544-52.
19. Marks WH, Ohlsson K. Elimination of pancreatic secretory trypsin inhibitor from the circulation. A study in man. Scand J Gastroenterol 1983;18:955-9.
20. Eddeland A, Ohlsson K. A radioimmunoassay for measurement of human pancreatic secretory trypsin inhibitor in different body fluids. Hoppe Seylers Z Physiol Chem 1978;359:671-5.
21. Kitahara T, Takatsuka Y, Fujimoto KI, Tanaka S, Ogawa M, Kosaki G. Radioimmunoassay for human pancreatic secretory trypsin inhibitor: measurement of serum pancreatic secretory trypsin inhibitor in normal subjects and subjects with pancreatic diseases. Clin Chim Acta 1980;103:135-43.
22. Haglund C, Huhtala ML, Halila H, Nordling S, Roberts PJ, Scheinin TM, et al. Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases. Br J Cancer 1986;54:297-303.
23. Osman S, Turpeinen U, Itkonen O, Stenman UH. Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Methods 1993;161:97-106.
24. Bradley EL. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, GA, September 11-13, 1992. Arch Surg 1993;128:586-90.
25. Pfutzer R, Barmada M, Brunskill A, Finch R, Hart P, Neoptolemos J, et al. SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. Gastroenterology 2000;119:615-23.
26. Chen JM, Mercier B, Audrezet MP, Ferec C. Mutational analysis of the human pancreatic secretory trypsin inhibitor (PSTI) gene in hereditary and sporadic chronic pancreatitis. J Med Genet 2000;37:67-9.
27. Kaneko K, Nagasaki Y, Furukawa T, Mizutamari H, Sato A, Masamune A, et al. Analysis of the human pancreatic secretory trypsin inhibitor (PSTI) gene mutations in Japanese patients with chronic pancreatitis. J Hum Genet 2001;46:293-7.
28. Kikuchi N, Nagata K, Yoshida N, Ogawa M. The multiplicity of human pancreatic secretory trypsin inhibitor. J Biochem (Tokyo) 1985;98:687-94.
29. Klaus W, Schomburg D. Solution structure of a variant of human pancreatic secretory trypsin inhibitor determined by nuclear magnetic resonance spectroscopy. J Mol Biol 1993;229:695-706.
30. Hecht HJ, Szardenings M, Collins J, Schomburg D. Three-dimensional structure of a recombinant variant of human pancreatic secretory trypsin inhibitor (Kazal type). J Mol Biol 1992;225:1095-103.
31. Sen JW, Bergen HR 3rd, Heegaard NH. On-line immunoaffinity-liquid chromatography-mass spectrometry for identification of amyloid disease markers in biological fluids. Anal Chem 2003;75:1196-202.